Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles  by Kim, Sang-Hyun et al.
Biochimica et Biophysica Acta 1788 (2009) 2150–2159
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemStructural modiﬁcations of outer membrane vesicles to reﬁne them as vaccine
delivery vehicles
Sang-Hyun Kim a,1, Keun-Su Kim a,c,1, Sang-Rae Lee a, Ekyune Kim a, Myeong-Su Kim a, Eun-Young Lee b,
Yong Song Gho b, Jung-Woo Kim c, Russell E. Bishop d,⁎, Kyu-Tae Chang a,⁎
a The National Primate Research Center (NPRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Chungbuk 363-883, Republic of Korea
b Department of Life Science, Pohang University of Science and Technology, San31 Hyoja-Dong, Nam-Gu, Pohang, Gyeongbuk 790-784, Republic of Korea
c Department of Animal Resource and Science, Dankook University, Anseo, Cheonan, Chungnam 330-714, Republic of Korea
d Department of Biochemistry and Biomedical Sciences, and the Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada L8N 3Z5⁎ Corresponding authors. R.E. Bishop is to be contacted a
fax: +1 905 522 9033. K.-T. Chang, tel.: +82 43 240 6300
E-mail addresses: bishopr@mcmaster.ca (R.E. Bishop
(K.-T. Chang).
1 Both authors contributed equally to this work.
0005-2736/$ – see front matter © 2009 Elsevier B.V. A
doi:10.1016/j.bbamem.2009.08.001a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 April 2009
Received in revised form 6 August 2009
Accepted 7 August 2009






Vaccine vehicleIn an effort to devise a safer and more effective vaccine delivery system, outer membrane vesicles (OMVs)
were engineered to have properties of intrinsically low endotoxicity sufﬁcient for the delivery of foreign
antigens. Our strategy involved mutational inactivation of the MsbB (LpxM) lipid A acyltransferase to
generate OMVs of reduced endotoxicity from Escherichia coli (E. coli) O157:H7. The chromosomal tagging of
a foreign FLAG epitope within an OmpA-fused protein was exploited to localize the FLAG epitope in the
OMVs produced by the E. coli mutant having the deﬁned msbB and the ompA::FLAG mutations. It was
conﬁrmed that the desired fusion protein (OmpA::FLAG) was expressed and destined to the outer
membrane (OM) of the E. coli mutant from which the OMVs carrying OmpA::FLAG are released during
growth. A luminal localization of the FLAG epitope within the OMVs was inferred from its differential
immunoprecipitation and resistance to proteolytic degradation. Thus, by using genetic engineering-based
approaches, the native OMVs were modiﬁed to have both intrinsically low endotoxicity and a foreign epitope
tag to establish a platform technology for development of multifunctional vaccine delivery vehicles.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
OMVs are spherical lipid bilayer vesicles that are extruded naturally
from the OM of Gram-negative bacteria [1]. The size of the membrane
vesicles ranges from ~20–200 nm in diameter, and they are composed
of characteristically antigenic OM constituents and some periplasmic
contents, suchasalkalinephosphatase andproteases, andevenDNAand
virulence factors [1,2]. Interestingly, a proteomic study showed that a
number of cytoplasmic proteins also constituted the proteome of E. coli
OMVs [3]. Thus, OMVs are nanosphere membrane vesicles having
intrinsic properties to be a vaccine carrier possessing thenative bacterial
antigens, as illustrated in Fig. 1. Currently, a new paradigm for vaccine
development has been emerging with non-replicating (acellular)
vaccine delivery systems characterized by usage of nano/micro-
particles, such as virus-like particles [4], liposomal vesicles such as
proteoliposomes [5], archaeosomes prepared from the polarmembrane
lipids of Archaea [6], and virosomes composed of some viral envelope
lipids [7]. In this respect, OMVs have notable advantages in vaccinet tel.:+1905 525 9140x28810;
; fax: +82 43 240 6309.
), changkt@kribb.re.kr
ll rights reserved.development over other lipidic nanoparticles. The native OMVs have a
multi-immunogenic capacity to carry a wide spectrum of endogenous
antigens, in addition to the natural self-adjuvanticity that is exerted by
toll-like receptor (TLR) agonists, such as outer membrane proteins
(OMPs), lipoproteins, and lipopolysaccharides (LPS). Beyond that,OMVs
are generally superior in enhancing phagocytic uptake, as their surface
molecules can be opsonized and/or recognized by the humoral
immunity components. Furthermore, OMVs can also be modiﬁed by
the inclusion of exogenous (synthetic) peptides and speciﬁc adjuvants,
which will provide the possibility of utilizing the reconstituted OMV as
anti-viral or anti-tumor therapeutic vaccines. Incorporation of addi-
tional functionality, such as ﬂuorescent dye conjugation, to the surface
components of OMVs couldmake themamore attractive biomaterial for
vaccine delivery studies in vivo.
In order to use these OMVs as vaccine delivery vehicles, safety issue
has to be addressed because native OMVs are composed of fully
endotoxic LPS, which provokes excessive secretion of proinﬂammatory
cytokines in humans and animals [8]. In efforts to reﬁne the OMV vector
system to be applicable for vaccination, we employed mutational
inactivationof themsbB gene encoding anacyltransferase catalyzing the
ﬁnal myristoylation step during lipid A biosynthesis [9,10]. It is known
that the penta-acylated LPS produced from the msbB mutants shows
reduced endotoxicity in human cells, compared with normal hexa-acyl
lipid A producers [11,12]. In this regard, we hoped to exploit OMVs of
Fig. 1. Proposed model for OMV production from genetically engineered E. coli O157:H7. The inactivation of MsbB activity and foreign epitope fusion to the OM-integral β-barrel
domain of OmpA can generate OMVs composed of mainly penta-acylated LPS and the C-terminally truncated OmpA tagged with a foreign epitope, as illustrated.
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potential for vaccination.
We reasoned that incorporation of a foreign epitope into the OMV
could be achieved by chromosomal tagging with DNA constructs
containing the foreign epitope DNA conjoined with homologous DNA
arms to be fused with ompA gene; the foreign epitope expressed with
OmpA in fusion should be targeted to the OM to result in the
spontaneous inclusion within the OMVs. If the foreign epitope in
OMVs that have reduced endotoxicity could be generated in themsbB
background harboring mainly penta-acylated LPS molecules, then
these OMVs would be desirable vaccine delivery vehicles because the
foreign epitope is physically linked to TLR agonistic adjuvants.
OmpA is one of the most abundant OM proteins in typical enteric
Gram-negative bacteria such as E. coli and Salmonella [13]. In addition
to its abundance, the well-characterized two-domain structure of
OmpA is advantageous to be fused with any sort of soluble foreign
proteins. The crystal structure of OmpA showed that the N-terminal
171 residues adopt the β-barrel domain, which traverses the OMwith
eight anti-parallel β-sheet segments, exposing four external loops on
the bacterial surface [14]. The remaining C-terminal portion of OmpA
protein was shown to reside in the periplasm [14]. A truncated OmpA
containing the N-terminal β-barrel domain but lacking as much as
132 amino acids from the periplasmic C-terminal domain was
conferring the truncated OmpA insertion and the OM stability [15].
Accordingly, by construction of an OmpA fusion with the FLAG
epitope as a model of the foreign epitope tagging in the OMV of the
msbB mutant of E. coli O157:H7, we successfully modiﬁed OMVs
intrinsically to be utilized as multifunctional vaccine delivery vehicles.
2. Materials and methods
2.1. Creation of msbB mutants in E. coli O157:H7
E. coli O157:H7 strain Sakai [16] was used as parental strain for
creation of gene-speciﬁc mutations by using one-step PCR mutagenesismethod [17]. Accordingly, theparentalE. coli stainwas transformedwith
pKD46, a temperature-sensitive plasmid carrying the Red recombinase
system from the λ bacteriophage under the control of the arabinose-
inducible pBAD promoter. The Red recombinase system mediates the
replacement of the target chromosomal sequence with an antibiotic
resistance cassette obtained by PCR ampliﬁcation using primers carrying
homologies to the vicinity on the gene targeted for disruption. The O157
E. coli carrying pKD46was transformed by electroporation with the PCR
product generated from a PCR with the template plasmid pKD3 as
described previously [17]. Transformants were plated in Luria–Bertani
(LB) agar, containing the appropriate antibiotics (chloramphenicol (Cm)
10 µg/ml; ampicillin (Amp) 100 µg/ml), and mutants were conﬁrmed
by PCR and DNA sequence analysis.
As previously reported, E. coli O157:H7 strains possess two
homologousmsbB genes: a chromosomalmsbB1 and a plasmid-encoded
msbB2 gene [18]. In order to inactivate MsbB activity, the two msbB
genes have to be disrupted at the same time. The sequential doublemsbB
mutations have been achieved in E. coliO157:H7by curing of pKD46 and
introduction of pCP20, leading to site-speciﬁc excision of the integrated
Cmcassette in either singlemsbBmutant (ΔmsbB1orΔmsbB2). Thus, the
other msbB gene targeting followed up with each single msbB mutant,
resulting in two separate mutants for the msbB1/msbB2 genes in the
E. coli O157:H7. The resulting two mutants were designated Sakai-DM1
for the msbB1/msbB2 sequence and Sakai-DM2 for the msbB2/msbB1
sequence. Since there was no phenotypic variation between these two
Sakai-DM mutants, Sakai-DM1 renamed as Sakai-DM (Supplementary
Table 1) was chosen for further OMV production studies.
2.2. Construction of Sakai-DM mutants carrying the ompA::FLAG and
pagP::FLAG fusions
As illustrated in Fig. 2A, intact ompA gene was cloned into
pBlueScript-II SK vector to construct a template plasmid for the
ompA::FLAG gene fusion assisted by the pKD46-encoding λ-Red
recombinase. At ﬁrst, a PCR amplicon called mega-primer DNA was
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MutOmpA-Flag) designed to encode 2×FLAG sequence (DYKDHDG-
DYKDHDDD) in themiddle of the primer sequence carrying homologies
to the C-terminal portion of the β-barrel domain of OmpA. Because a
stop codon was incorporated into the end of the 2×FLAG-encoding
primer sequence, the reading frame for the OmpA::FLAG has to be
terminated after the processed N-terminal β-barrel domain of OmpA,
thus lacking the C-terminal portion for the periplasmic domain. Theﬁrst
PCR productwas then used as amega-primer for the second step PCR to
amplify the mutated allele containing the 2×FLAG sequence, thus
resulting in the DNA encoding OmpA::FLAG fusion protein. Then, as
selectable marker for the allelic replacement, the Cm cassette derived
from pKD3 was placed in between the H2 and H3 homologies to the
chromosomal DNA of E. coli O157:H7. The H2 and H3 regions in the
mutagenic template DNA are meant to represent DNA sequence
homologies to the target chromosomal DNA regions which would
facilitate homologous recombination events. High-ﬁdelity PCR was
performed with a proofreading DNA polymerase (Advantage-HF2 PCR
kit, BD Biosciences-Clontech, CA) as follows; denaturation at 94 °C forFig. 2. Recombinant DNA strategy (A) used to achieve the ompA::FLAG allelic replacement
procedure was conducted by using the mutagenic mega-primer method. The Cm cassette (F
the downstream ompA gene was cloned into the template plasmid for the ompA gene targetin
methods. In panel B, the potential mutant carrying the ompA::FLAG allele conjoined with
conﬁrmed by cleavage of the amplicon with PsiI that cuts the FLAG sequence speciﬁcally. Lan
the parental strain, 2: the amplicon corresponding to the ompA::FLAG allele conjoined with30 s, annealing at 55 °C for 1 min, and elongation at 70 °C for 2 min.
Transformants with the ampliﬁed allele were plated in LB agar,
containing the Cm antibiotic, and the potential mutants were screened
by PCR with a pair of Forw-1 and Rev-2 primers (Supplementary
Table 1). Then, the resulting mutant (Sakai-DM/ompA::FLAG) was
conﬁrmed by PsiI digestion and DNA sequencing of the amplicon
obtained from PCR with Forw-1 and Rev-2 primers.
A similar allelic exchange strategywasemployed in the generationof
pagP::FLAG mutation in Sakai-DM mutant, with a view to producing
strictly penta-acyl lipid A species by inactivation of PagP-mediated
palmitoylation in the OM of Sakai-DM. In this case, pagP DNA region
encoding the extracellular loop-1was geneticallymanipulated to delete
eight amino acid residues (YDKEKTDR) within the loop-1 of PagP and
insert the FLAG sequence into the deleted region, so that the 8 residues
of the PagP loop-1 can be in-framely replaced by the 2×FLAG residues.
The previously described mega-primer PCR method by using a
mutagenic reverse primer called MutPagP-Flag (Supplementary
Table 1) was used for construction of the pagP::FLAG allelic template
DNA. Then, the Cm-cassette and H3 homology fragment was placed inin the E. coli mutant (B). In panel A, a sequential PCR-based site-directed mutagenesis
RT–Cm–FRT) originated from the pKD3 plasmid and the H3 fragment corresponding to
g with the ampliﬁed DNAwith Forw-1 and Rev-2 primers, as described in Materials and
the Cm-cassette (PCR products with Forw-1 and Rev-2 primers) was screened and
es M: size marker (1-kb ladder, Fermentas), 1: the ampliﬁed DNA for intact ompA from
the Cm-cassette in the mutant, and 3: the PsiI-digested amplicon from the mutant.
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targeting, screening and conﬁrmation of the mutants harboring the
pagP::FLAG allele were conducted by the same way described in the
ompA::FLAG mutation previously. The resulting mutant was character-
ized and named Sakai-DM/pagP::FLAG.
2.3. Preparation of OMVs
OMVs were prepared as described previously [19] with slight
modiﬁcations. Brieﬂy, E. coli O157:H7 and its isogenic mutants were
inoculated into 500 ml of LB broth and cultured overnight at 37 °C
shaker. The bacteria were then pelleted by centrifugation (11,000×g)
for 30 min at 4 °C. The resulting supernatant was recovered and
further passed through 0.22 μm pore-size ﬁlter. The OMVs were
harvested from the ﬁltered supernatant by precipitation using
ammonium sulfate (390 g/l, ﬁnal concentration). After the ammoni-
um sulfate was added and completely dissolved, the mixture was left
at 4 °C overnight to precipitate. Then, OMV was collected by
centrifugation at 11,000×g for 30 min. The pellet was resuspended
in 20 ml of phosphate-buffered saline (PBS) and centrifuged again at
16,000×g for 15 min at 4 °C. OMVs remained in the supernatant were
collected by centrifugation at 100,000×g for 2 h at 4 °C. The crude
OMV-pellet obtained by the differential centrifugation was resus-
pended in 3 ml of PBS for further OMV puriﬁcation by using sucrose-
gradient ultracentrifugation step [3].
2.4. LPS preparation and SDS-PAGE analysis
LPSwas prepared on a small scale from thewhole-cell lysatemethod
by using SDS-proteinase K treatment [20]. For LPS dry-weight
determination, LPS isolated from each sample was extensively dialyzed
against water, and the dialysate was lyophilized. Then, the lyophilized
LPS wasweighed on a balance. The LPS sample was dissolved in 2×SDS
sample buffer, and boiled for 10 min prior to loading on a 16% Tricine
SDS-PAGE gel (Novex, San Diego, CA). Then, the separated LPS bands
were visualized by silver staining.
2.5. Analysis of radiolabeled lipid A by TLC
TLC experiments were performed to analyze the compositional
variation of lipid A species isolated from the various mutants, as
described previously [21]. The lipid A sample was dissolved in 100 µl
of chloroform/methanol (4:1, v/v), and 1,000 cpm of the sample was
applied to the origin of a Silica Gel 60 TLC plate. TLC was conducted in
a developing tank in the solvent chloroform/pyridine/88% formic
acid/water (50:50:16:5, v/v). The plate was dried and visualized with
an imaging analyzer (FLA-7000, FUJIFILM).
2.6. OMP proﬁles of the OM and OMV fractions
The OMPs of bacterial cells were prepared by a differential
solubilization of total membrane proteins with N-lauroylsarcosine [22].
The total membrane fraction was resuspended in 20 mM Tris–HCl
(pH 7.5) containing 1% (wt/vol) sodium lauryl sarcosine, and incubated
at room temperature for 30 min to dissolve the detergent-soluble
cytoplasmic membrane fraction. Then, the sarcosine insoluble OM
fraction was separated by centrifugation at 45,000×g for 90 min, and
the OM pellet was washed twice with deionized water. The OMPs
derived from the bacterial cells and the OMVs were then separated on a
SDS–14% polyacrylamide gel and were visualized by staining with
Coomassie blue G-250.
2.7. Western and dot blot analyses of the OMV fractions
Appropriate portion of the OMVs was analyzed by blotting onto
nitrocellulose membrane (Invitrogen, USA). The mouse monoclonalantibody to FLAG epitope (Sigma, USA) and the peroxidase-conjugated
rabbit anti-mouse IgG (Sigma, USA) were used for detection of the
OmpA::FLAG-epitopeprotein in theOMandOMVs. Thedilution ratiosof
both antibodies were 1:5000.2.8. Electron microscopy
For OMV visualization by electron microscopy, OMVs were nega-
tively stained and observed with a transmission electron microscopy
(TEM). Brieﬂy, A formvar-coated gridwasﬂoated on a droplet of sample
onparaﬁlm for 1 min topermit adsorptionof the specimen. The gridwas
then transferred onto a drop of negative stain (1% uranyl acetate) for
30 s, blotted with a ﬁlter paper, and then air-dried. The sample was
examined under CM20 transmission electron microscope (Philips,
Netherlands). For visualization of OMV blebbing from the E. coli, the
colonies grown overnight on LB plate at 37 °Cwere lifted and then ﬁxed
in 2.5% paraformaldehyde–glutaraldehydemixture bufferedwith 0.1 M
phosphate (pH 7.2) for 2h. The samples were postﬁxed in 1% osmium
tetroxide in the same buffer for 1h, dehydrated in graded ethanol and
propylene oxide, and embedded in Epon-812. Ultra-thin sections, made
by ULTRACUT E ultramicrotome (Leica, Austria), were stained with
uranyl acetate and lead citrate and examined under CM20 transmission
electron microscope (Philips, Netherlands).2.9. Endotoxicity (nuclear factor-κB induction) assay
The induction of NF-κB due to TLR4 activation by LPS stimulation
was quantiﬁed using HEK-Blue™-4 cells (InvivoGen, USA). The LPS
responding cells employed in this system are HEK293 cells stably
transfected with TLR4, MD2, CD14, as well as secreted embryonic
alkaline phosphatase (SEAP) under the control of a promoter
inducible by NF-κB, resulting that extracellular SEAP in the superna-
tant is proportional to NF-κB induction. HEK-Blue™-4 cells main-
tained in HEK-Blue™ selection medium containing zeocin and
normocin, were incubated at a density of ~1×105 cells/ml in a
volume of 180 μl/well, in 96-well ﬂat-bottomed cell culture plate with
the LPS stimuli, until conﬂuencywas achieved (20–24 h). Colorimetric
assays for SEAP induction were measured using an AP-speciﬁc
chromogen (QUANTI-Blue™) by spectrophotometer at 620 nm, as
recommended in the vendor's instruction. All samples were run in
triplicate, from which means and SD were determined.2.10. Trypsinization and immunoprecipitation of OMVs
Trypsin was added to OMV (1 mg/ml in PBS) at a ﬁnal concen-
tration of 100 μg/ml and allowed to react for the indicated times at
37 °C. Digestion was stopped by addition of SDS sample buffer and
immediate boiling of the digested sample for 5 min, prior to SDS-PAGE
(14% gel) and western blot analyses with anti-OmpA and anti-FLAG
antibodies.
For immunoprecipitation (IP), the puriﬁed OMVs and the OMV
lysate prepared by rupturing the vesicles with sodium deoxycholate
(ﬁnal 1% solution)were resuspended in IPwash buffer (10 mMTris/pH
7.4, 1 mMEDTA, 150 mMNaCl, and 1% Triton X-100), and incubated for
2 h at 4 °C with 5 μg anti-FLAG monoclonal antibody or rabbit anti-
OmpA polyclonal antibody with gentle rotation, respectively. Then,
immune complexes formed in the reactionmixturewere capturedwith
protein G-agarose beads (pre-blocked with 1% BSA) by incubation
overnight at 4 °C with gentle rotation. Beads were pelleted by
centrifugation (2000×g, 1 min, 4 °C), washed three times with the IP
wash buffer. After careful removal of the ﬁnal wash, the pellet was
resuspended in SDS sample buffer, and boiled for 5 min prior to SDS-
PAGE and western analysis.
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3.1. MsbB-deﬁcient mutant of E. coli O157:H7 and its derivatives
Since endotoxicity of LPS has long been recognized as an obstacle to
thedevelopmentof the LPS-containingvaccines, effortshavebeenmade
previously in ﬁnding ways of rendering the LPS molecules non-
endotoxic. Inactivation of msbB in Gram-negative bacteria causes a
marked reduction of LPS endotoxicity [23–25]. Accordingly, we created
an E. coliMsbB-deﬁcient mutant, which produces LPS consisting of the
penta-acylated lipid A precursor [9–11]. The resulting MsbB-deﬁcient
mutant of E. coli O157 Sakai strain (Sakai-DM) was used as parental
strain to introduce the deﬁned ompA::FLAG and pagP::FLAG mutations,
respectively, in the MsbB-deﬁcient background.
The ompA::FLAG mutation was created in order to introduce the
FLAG tag onto the OM and OMVs of the MsbB-deﬁcient mutant. As
illustrated in Fig. 2A, the DNA sequence of a short peptide epitope can
be incorporated in the mutagenic primer sequence, leading to an in-
frame fusion with the target protein. However, when a larger protein
domain needs to be incorporated, the H2 homology extension placed
between the fusion site (bricks) and the Cm cassette (checker) can be
entirely substituted with the cloned protein domain gene. In the case
of FLAG tagging used in this study, a selectable restriction site (PsiI)
was spontaneously introduced within the FLAG sequence, which
allows easy screening of the potential mutants as exempliﬁed in the
conﬁrmation of the PCR product for the ompA::FLAG ampliﬁed from
the desired mutant (Fig. 2B).
In the analysis of whole LPS molecules, no distinct change of LPS
expression was noted except that the mainly penta-acylated LPS
molecules migrate faster than the hexa-acylated LPS of wild type
O157 Sakai (Fig. 3A). For analysis of the lipid A moiety, TLC
experiments were conducted as described previously [27]. The
major lipid A species in E. coli is phosphorylated at position-1, but
lesser amounts can contain 1-diphosphoryl or 1-diphosphoryletha-
nolamine moieties. The hexa-acylated 1-phosphoryl lipid A species
disappeared completely only in the Sakai-DM/pagP::FLAG mutant
(lane 4, Fig. 3B), demonstrating that the remaining palmitoylatedFig. 3. LPS (lipid A) proﬁles of the O157 E. colimutants. The silver-stained LPS samples separ
pagP::FLAG. In panel B, 32P-labelled lipid A species were separated by TLC and imaged. Note
Interestingly, there is a small fraction of penta-acylated lipid A species found in the Saka
palmitoylated (hexa-acyl) lipid A (lane 5) occurred in Sakai-DM, this MsbB-deﬁcient muta(hexa-acyl) lipid A molecules in Sakai-DM (lane 5) were PagP-
dependent [28]. Initially, the pagP::FLAG mutation was designed for
inactivation of PagP by incorporation of a FLAG tag into the mutated
loop-1 region of the protein so as to monitor the level of expression in
the OM. We conﬁrm that such an in-frame deletion of the eight
(YDKEKTDR) residues in the catalytically active extracellular loop-1
region of PagP [26] can abolish the PagP-mediated palmitoylation of
lipid A in Sakai-DM, giving rise to the strictly penta-acylated LPS in the
msbB-deﬁcient background. The assignments of lipid A species in
Fig. 3B were based on the previous studies [27,28].
The penta-acylated lipid A species is known to be a much weaker
agonist for the induction of proinﬂammatory cytokines through the
TLR4–MD2 receptor complex [8,10]. In order to assess reduction of
endotoxicity mediated bymodiﬁed LPS isolated from the O157mutants
(Sakai-DM and Sakai-DM/pagP), we determined the level of NF-κB
induction in the LPS treated HEK-Blue™-4 cells by measuring
absorbance from the SEAPdetection system. Themodiﬁed LPS produced
from themsbBmutant showed a signiﬁcant reduction in the activation
of NF-κB, compared to that ofwild type (Fig. 4). These results from the in
vitro assay suggest that OMVs harboring mainly penta-acylated lipid A
species would display reduced endotoxicity compared to the native
OMVs that possess hexa-acylated lipid A species. The difference ofmean
OD values in all 3 LPS samples was statistically signiﬁcant when
analyzed by one-way ANOVA (p-valueb0.05).
3.2. TEM observations of OMVs
In electron microscopic observations (Fig. 5), OMVs of Sakai-DM
derivatives were shown as nanosphere vesicles with variable sizes
ranging from 40–100 nm in diameter. Crude OMVs (Fig. 5A) collected
from the culture supernatant were puriﬁed by using sucrose-density
gradient ultracentrifugation [3]. The puriﬁed OMVs pooled from the
fractions 5 to 10 (Fig. 5C) gave a clear TEM image of OMVs (Fig. 5D).
Interestingly, the msbB mutation increased the amounts of OMVs
compared with wild type (data not shown), which might be due to the
compromised OM permeability barrier observed in the MsbB-deﬁcient
mutant [18,28].ated by SDS-PAGE are shown in panel A. Lanes 1: Sakai-WT, 2: Sakai-DM, 3: Sakai-DM/
that the deﬁciency of both MsbB and PagP abolished the hexa-acylated lipid A (lane 4).
i-M1 (lane 2), in contrast to Sakai-WT (lane 1) and Sakai-M2 (lane 3). Although the
nt mainly produced penta-acyl (low-endotoxic) lipid As.
Fig. 4. Endotoxicity assessed by the level of NF-κB activation in the LPS treated HEK-
Blue™-4 cells. The level of NF-κB induction was measured by using the SEAP detection
system supplied with HEK-Blue™-4 cells (InvivoGen, USA) after treatment with the
puriﬁed LPS samples from the O157 wild type and its mutants (Sakai-DM and Sakai-
DM/pagP). The modiﬁed LPS of themsbB and msbB/pagPmutants showed a signiﬁcant
reduction in the activation of NF-κB, compared to that of wild type. The difference of
mean OD values in the all 3 LPS samples was statistically signiﬁcant when analyzed by
one-way ANOVA (p-valueb0.05).
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In the comparison of the OMP proﬁles (left panel, Fig. 6), unlike the
Sakai wild type (lane 1) and Sakai-DM (lanes 2 and 4), the OM proteinsFig. 5. TEM observations of OMVs released from the O157 E. coli mutants. The OMVs in t
respectively. OMV fractionation (C) by sucrose-density gradient ultracentrifugation was con
OMV fractions from 5 to 10 were shown (D).of Sakai-DM/ompA::FLAG (lanes 3 and 5) showed a distinctive OmpA
truncation (lacking the 35 kDa band, but with a ~22 kDa band present);
this observation is consistent with the designed C-terminal OmpA
truncation and FLAG epitope (DYKDHDGDYKDHDDD) fusion conjoined
with a stop codon between residues 174-175 of the OmpA protein.
Western blot analysis (right panel, Fig. 6) demonstrated that the
OmpA::FLAG protein was speciﬁcally detected by using anti-FLAG
monoclonal antibody (Sigma, USA). These results suggest that the FLAG
epitope fused to the β-barrel domain of OmpA can be expressed and
successfully inserted into theOMwithout the remaining 151 residues of
the C-terminal periplasmic domain of OmpA. Thus, the OmpA::FLAG
protein was spontaneously incorporated into the OMVs when released
during growth. Because OmpA is a structurally well-characterized and
abundant OMprotein, the foreign epitope fusion to theβ-barrel domain
of OmpA can be nicely utilized for tagging of OMVswith diverse foreign
epitopes. Furthermore, OmpA has been known to have antigen carrier
properties utilized for internalization of coupled foreign antigens by
antigen-presenting cells and to prime CD8+ cytotoxic T lymphocytes
(CTL), indicating that it can be a fusion target for exogenous antigen
coupling to elicit therapeutic CTL responses [29].
3.4. Folding status of OmpA::FLAG protein
Because the electrophoretic mobility of the folded β-barrel mem-
brane proteins on SDS-PAGE can differ from that of the fully denatured
forms if the samples are not boiled prior to electrophoresis, this so-he culture supernatant (A) and the colonies (B) of Sakai-DM mutant were observed,
ducted with crude OMVs released from Sakai-DM/ompA::FLAG mutant, and the pooled
Fig. 6. Expression of the OmpA::FLAG in the OM and OMVs. The OmpA::FLAG protein was veriﬁed with the OM and OMVs samples by using anti-FLAG monoclonal antibody. The
OmpA::FLAG protein (22 kDa bands, lanes 3 and 5) was only detected in the OM (lane 3) and the OMVs (lane 5) of Sakai-DM/ompA::FLAG. Lanes 1: OMPs of Sakai-WT, 2 and 4:
Sakai-DM, and 3 and 5: Sakai-DM/ompA::FLAG.
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assessing OMP folding [35,36]. We exploited this phenomenon to
provide evidence for the folding status of OmpA::FLAG, as a truncated
form of OmpA, in the OM. Using this assay, we showed that the folded
OmpA (no boiling) migrates faster than the unfolded (boiling)
conformation (Fig. 7). Interestingly, however, the OmpA::FLAG in the
OM showed a different migration pattern as opposed to that of intact
OmpA, that is, the unfolded OmpA::FLAG (denatured by boiling)
migrates faster than the folded β-conformation (Fig. 7). This kind of
inverse shift has been reported in the case of PagP, which is an 8-
stranded β-barrel OMP composed of 161-residues [37]. Collectively,
these inverse shifts of heatmodiﬁability suggest that theOmpA::FLAG is
correctly folded as a β-barrel conformer (Fig. 8) in the OM and OMVs of
the mutant.Fig. 7. Heat modiﬁability of intact and the truncated forms of OmpA proteins in SDS-PAGE. Th
PAGE. Folded OmpA (~30 kDa band) migrates faster than the heat-unfolded conformatio
(~22 kDa band) migrates faster than the folded β-conformation (right panel). This inverse sh
FLAG, suggesting that the OmpA::FLAG is correctly folded as a β-barrel conformer in the O3.5. Immunoprecipitation (IP) and trypsinization of OMVs
IP and OMV trypsinization were carried out to provide evidences
that the FLAG epitope fused C-terminally in truncated OmpA could be
localized in the lumen of the OMVs containing the OmpA::FLAG; this
luminal localization of a foreign antigen will protect it from
proteolysis by host proteases when the OMV is given for host
immunization by possible mucosal routes. In IP experiments, the
OMVs treated with anti-OmpA antibodies were immunoprecipitated
and, subsequently, the OMVs containing the OmpA::FLAG were
speciﬁcally detected by western blotting with anti-FLAG monoclonal
antibody and compared with control OMVs containing intact OmpA
(lane 1, Fig. 9B). When the OM and OMV lysates (Fig. 9A and C) were
interrogated by anti-FLAG for IP and western blot, the OmpA::FLAGe folding of de novo-expressed OmpA::FLAG was assessed by heat modiﬁability in SDS-
n (35 kDa band) in SDS-PAGE (left panel). However, the heat-unfolded OmpA::FLAG
ifting in the mobility of OmpAmight be due to the C-terminal truncation in the OmpA::
M.
Fig. 8. Proposed topology for the OmpA::FLAG protein in the OM. The proposed OM topology of the integral OmpA::FLAG protein is shown. Since OmpA amino acid residues up to G-171
have been structurally characterized to comprise the N-terminal β-barrel domain [14], the C-terminally tagged FLAG peptide (shaded) to the 174th residue has to be located in the
periplasmic side, thus the introduced foreign epitope can be spontaneously entrapped in the lumen of theOMVs. The inset shows that OMVs containing theOmpA::FLAGwere speciﬁcally
detected by dot blot analysis.
Fig. 9. Immunoprecipitation and trypsinization of OMVs. In IP experiments (A, B, and C), the OMVs treated with anti-OmpA antibodies were immunoprecipitated and, subsequently, the
OMVscontaining theOmpA::FLAG(lane2of panel B)werespeciﬁcallydetectedbywesternblottingwithanti-FLAGmonoclonal antibodyandcomparedwith controlOMVs containing intact
OmpA (lane 1 of panel B). When the OM (A) and OMV (C) lysates were interrogated by anti-FLAG for IP and western blot, the OmpA::FLAG band was only detected in those lysates from
Sakai-DM/ompA::FLAG (lane2, panel A), comparedwith Sakai-DM(lane1, panelA). These results suggest that theFLAGepitope(foreign antigen) fused in theOmpA::FLAG is localized in the
lumen of the OMVs. Panels D and E were western blots of trypsinized OMVs containing the OmpA::FLAG probed with anti-OmpA (D) and anti-FLAG (E) antibodies, respectively.
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(lanes 2, Fig. 9A and C), compared with Sakai-DM control (lanes 1).
Conversely, when intact OMVs were interrogated by IP and western
blot with anti-FLAG antibody, there was no signal detected (data not
shown). These results suggest that the FLAG epitope (foreign antigen)
fused in the OmpA::FLAG was not localized on the surface of the
OMVs.
In the OMV trypsinization (panels D and E), the OmpA::FLAG
proteins remained undigested after the speciﬁed time of trypsiniza-
tion at 37 °C, suggesting that FLAG epitope fused to the OmpA β-barrel
domain was not accessible to trypsin digestion because of the folding
conﬁguration of the OmpA::FLAG protein in the OMVs. Consistent
with the folding of the OmpA::FLAG probed by heat modiﬁability
(Fig. 7), these data indicate that the foreign epitope fused to the OmpA
β-barrel domain can be incorporated into the OMVs with a luminal
exposure that protects them from proteolytic digestion.
3.6. A model for foreign epitope tagging to OMVs is established
The foreign FLAG epitope fused to the β-barrel domain of OmpA
can be localized to the periplasmic side of the OM when correctly
folded. Subsequently, the foreign epitope can be spontaneously
entrapped in the lumen of the OMVs (Figs. 1 and 8). Accordingly,
the foreign epitope localized inside the OMV is protected from
proteolysis (Fig. 9). This model for foreign epitope tagging to the
OMVs by using the OmpA-fusion approach should be applicable to any
sizable choice of soluble antigens, because the H2 homology extension
(Fig. 2A) can be entirely replaced by the target gene encoding any
antigenic protein to be fused for the induction of the antigen-speciﬁc
immune responses by the delivery of the OMV/OmpA-carrier. OmpA
shows diverse functions in adherence and invasion of host cells, and
induces maturation of dendritic cells via signaling through TLR2
[29,30]. Those foreign proteins fused to OmpA are thus physically
linked to strong adjuvants in the OMV vaccine vehicle.
Cattle infected by E. coli O157:H7 pose a constant threat to infect
humans due to the consumption of contaminated beef [30,31]. To
prevent the transmission of this pathogen from beef to humans,
vaccination of cattle is considered as a promising approach to reduce
intestinal colonization and shedding of this microorganism. In this
regard, the FLAG-tagged OMVs from E. coli O157:H7 can be a vaccine
candidate, not only for the induction of mucosal immunity, but also
for allowing the differentiation of naturally-infected versus vaccinat-
ed animals because of the positive serology against the FLAG-tag,
which could be used as a vaccination marker.
In the present study, we devised OmpA::FLAG-tagged OMVs in
which the endogenous LPS molecules are composed primarily of the
penta-acylated (much less-endotoxic) rather than hexa-acylated (fully
endotoxic) lipid A moiety. By genetic manipulations E. coli O157:H7
mutants were created to transform their OMVs into an antigen delivery
vehicle, which is a potential candidate for a safer, multi-immunogenic,
and self-adjuvanted nanosphere vaccine vehicle. Recently, promising
results have accumulated in experimental vaccinationwith somenative
OMVs from diverse pathogenic Gram-negative bacteria [32–34]. The
strategy we have used for the OMV modiﬁcations in this study will be
further applied to the development of multifunctional OMV vaccine
delivery vehicles. Although inﬂammatory agonists other than lipid A are
present in OMVs, reducing lipid A toxicity represents an important ﬁrst
step toward OMV detoxiﬁcation.
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